文献速递类风湿关节炎

支持自我管理与远程监测疾病影响的移动应用程序用于类风湿关节炎:随机对照AEGORA试验

A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomized controlled AEGORA trial.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

AEGORA为多中心随机对照试验,122例类风湿关节炎患者按2:1:1分配至常规照护或两种基于应用程序的自我管理干预(每周或每月远程监测RAID)。16周时干预未改善关节炎自我效能量表评分(β 0.44,P=0.87),疼痛灾难化量表非劣效成立(β -0.95 [95%CI -3.30, +1.40] favouring干预),应用程序留存率降至43%,35%的应用使用者报告至少1次临床相关恶化。

要点

  • 应用程序自我管理干预16周未改善关节炎自我效能(β 0.44,P=0.87)。
  • 疼痛灾难化量表非劣效成立(β -0.95 [95%CI -3.30, +1.40] favouring干预)。
  • 16周时应用程序留存率降至43%,35%应用使用者报告至少1次临床相关RAID恶化。

核心结论

  • 基于应用程序的自我管理干预在改善自我效能方面不优于常规照护,但远程症状监测未增加疼痛灾难化,减轻了对应用程序远程监测心理影响的担忧。

研究设计与样本

  • 多中心随机对照试验,按2:1:1分配至常规照护或两种版本的基于应用程序的类风湿关节炎自我管理干预,共纳入122例患者,16周 programme 包括患者教育、目标设定和远程监测RAID(每周或每月,取决于随机分组)。

主要发现

  • 共纳入122例患者,平均(标准差)病程12(9)年,年龄58(11)岁,女性68%,DAS28-CRP 2.4(0.9)。
  • 干预未改善关节炎自我效能量表评分(β 0.44,P=0.87)。
  • 疼痛灾难化量表非劣效成立(β -0.95 [95% CI -3.30, +1.40] favouring干预)。
  • 其他预设结局无差异。
  • 应用程序留存率稳步下降至16周时43%;RAID总体随时间保持稳定,但35%的应用使用者报告16周内至少1次临床相关恶化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this work was to determine whether smartphone applications could support the self-management of RA and to investigate engagement and potential negative psychological effects with app-use. METHODS: App-based Education and GOal-setting in RA (AEGORA) was a multicentre randomized controlled trial with 2:1:1 allocation to usual care or two versions of an app-based self-management intervention for RA. The 16-week programme involved patient education, goal-setting and remote monitoring of the Rheumatoid Arthritis Impact of Disease (RAID) instrument, either weekly or monthly depending on randomization. The primary end point was improvement in the Arthritis Self-Efficacy Scale (ASES) after 16 weeks. Secondary endpoints included non-inferiority regarding the Pain Catastrophizing Scale (PCS) and superiority regarding patient-reported physical activity, sleep quality and RAID. App engagement and RAID scores were analysed descriptively. RESULTS: Overall, 122 patients were included: mean (s.d.) disease duration 12 (9) years, age 58 (11), 68% female, DAS28-CRP 2.4 (0.9). The intervention did not improve the ASES score over usual care (β 0.44, P = 0.87). Non-inferiority was established for the PCS (β -0.95 [95% CI -3.30, +1.40] favouring the intervention). Other predefined outcomes did not differ. App retention steadily declined to 43% by 16 weeks. Although the RAID remained stable over time overall, 35% of app users reported ≥1 episode of clinically relevant worsening over 16 weeks. CONCLUSION: This app-based self-management intervention was not superior to usual care regarding self-efficacy improvement. However, remote symptom monitoring provided valuable insight and did not increase pain catastrophizing, alleviating concerns regarding the psychological impact of remote monitoring with apps. TRIAL REGISTRATION NUMBER: clinicaltrials.gov, NCT05888181.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Doumen M, De Meyst E, Bertrand D, et al. A mobile app to support self-management and remotely monitor disease impact in rheumatoid arthritis: the randomized controlled AEGORA trial. Rheumatology (Oxford). 2025. PMID: 39576683. doi:10.1093/rheumatology/keae638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。